This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Aragon Pharmaceuticals, Inc.. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: The Innovative Contributions of Caly Chien
Introduction
Caly Chien is a prominent inventor based in Princeton, NJ (US). She has made significant strides in the field of medical research, particularly in the treatment of prostate cancer. Her work focuses on developing innovative solutions that address critical health challenges.
Latest Patents
Caly Chien holds a patent for "Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment." This patent describes methods of treating non-metastatic castration-resistant prostate cancer in patients with severe hepatic impairment using androgen receptor inhibitors. One of the compounds mentioned in her patent is 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. She has 1 patent to her name.
Career Highlights
Caly Chien is currently associated with Aragon Pharmaceuticals, Inc., where she continues to contribute to groundbreaking research in oncology. Her work has the potential to significantly improve treatment options for patients suffering from prostate cancer.
Collaborations
Caly collaborates with notable colleagues, including Alex Yu and Peter Hellemans, who share her commitment to advancing medical science and improving patient outcomes.
Conclusion
Caly Chien's innovative work in the field of cancer treatment exemplifies the impact of dedicated research and development. Her contributions are paving the way for new therapeutic options that could benefit many patients in need.